Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.

ABSTRACT:

Background

Patients with chronic obstructive pulmonary disease (COPD) who were naive to anticholinergics before the TIOtropium Safety and Performance In Respimat (TIOSPIR) trial may reflect patients seen in practice, in particular in primary care. In addition, investigating safety in these patients avoids the potential bias in patients who previously received anticholinergics and may be tolerant of their effects.

Aims

The aim of this study was to evaluate whether patients naive to anticholinergic therapy who were treated with tiotropium Respimat 2.5 or 5 μg had different safety and efficacy outcomes than patients treated with tiotropium HandiHaler 18 μg.

Methods

A post hoc analysis of patients who were not receiving anticholinergics before TIOSPIR (N=6,966/17,135) was

SUBMITTER: Wise R 

PROVIDER: S-EPMC4634206 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature